| Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study A Jaccard, N Gachard, B Marin, S Rogez, M Audrain, F Suarez, H Tilly, ... Blood, The Journal of the American Society of Hematology 117 (6), 1834-1839, 2011 | 410 | 2011 |
| Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial R Delarue, H Tilly, N Mounier, T Petrella, G Salles, C Thieblemont, ... The lancet oncology 14 (6), 525-533, 2013 | 363 | 2013 |
| Rituximab plus lenalidomide in advanced untreated follicular lymphoma F Morschhauser, NH Fowler, P Feugier, R Bouabdallah, H Tilly, ... New England Journal of Medicine 379 (10), 934-947, 2018 | 341 | 2018 |
| The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL … C Thieblemont, J Briere, N Mounier, HU Voelker, W Cuccuini, E Hirchaud, ... J Clin Oncol 29 (31), 4079-4087, 2011 | 336 | 2011 |
| Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions M Levade, E David, C Garcia, PA Laurent, S Cadot, AS Michallet, ... Blood, The Journal of the American Society of Hematology 124 (26), 3991-3995, 2014 | 320 | 2014 |
| Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma L Vercellino, R Di Blasi, S Kanoun, B Tessoulin, C Rossi, M D'Aveni-Piney, ... Blood advances 4 (22), 5607-5615, 2020 | 270 | 2020 |
| Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib D Ghez, A Calleja, C Protin, M Baron, MP Ledoux, G Damaj, M Dupont, ... Blood, The Journal of the American Society of Hematology 131 (17), 1955-1959, 2018 | 252 | 2018 |
| Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation S Kamel, L Horton, L Ysebaert, M Levade, K Burbury, S Tan, ... Leukemia 29 (4), 783-787, 2015 | 250 | 2015 |
| Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma C Herbaux, J Gauthier, P Brice, E Drumez, L Ysebaert, H Doyen, ... Blood, The Journal of the American Society of Hematology 129 (18), 2471-2478, 2017 | 244 | 2017 |
| Expression of β-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis L Ysebaert, G Chicanne, C Demur, F De Toni, N Prade-Houdellier, ... Leukemia 20 (7), 1211-1216, 2006 | 238 | 2006 |
| Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study E Bachy, JF Seymour, P Feugier, F Offner, A López-Guillermo, D Belada, ... Journal of Clinical Oncology 37 (31), 2815, 2019 | 220 | 2019 |
| Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial JA Jones, T Robak, JR Brown, FT Awan, X Badoux, S Coutre, ... The Lancet Haematology 4 (3), e114-e126, 2017 | 211 | 2017 |
| What lessons can be learned from γδ T cell-based cancer immunotherapy trials? JJ Fournié, H Sicard, M Poupot, C Bezombes, A Blanc, F Romagné, ... Cellular & molecular immunology 10 (1), 35-41, 2013 | 201 | 2013 |
| Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies J Gertner-Dardenne, C Bonnafous, C Bezombes, AH Capietto, ... Blood, The Journal of the American Society of Hematology 113 (20), 4875-4884, 2009 | 192 | 2009 |
| Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis C Laurent, C Do, RD Gascoyne, L Lamant, L Ysebaert, G Laurent, ... J clin oncol 27 (25), 4211-4216, 2009 | 190 | 2009 |
| Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis C Recher, L Ysebaert, O Beyne-Rauzy, V Mansat-De Mas, JB Ruidavets, ... Cancer research 64 (9), 3191-3197, 2004 | 189 | 2004 |
| MYC + diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation W Cuccuini, J Briere, N Mounier, HU Voelker, A Rosenwald, C Sundstrom, ... Blood, The Journal of the American Society of Hematology 119 (20), 4619-4624, 2012 | 186 | 2012 |
| A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia F De Toni, C Racaud-Sultan, G Chicanne, V Mas, C Cariven, F Mesange, ... Oncogene 25 (22), 3113-3122, 2006 | 172 | 2006 |
| Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVδ1 and TCRVδ2 γδ T lymphocytes G Pizzolato, H Kaminski, M Tosolini, DM Franchini, F Pont, F Martins, ... Proceedings of the National Academy of Sciences 116 (24), 11906-11915, 2019 | 166 | 2019 |
| Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study PA Thompson, V Lévy, CS Tam, C Al Nawakil, FX Goudot, A Quinquenel, ... British journal of haematology 175 (3), 462-466, 2016 | 139 | 2016 |
Jean Jacques FourniéCentre de Recherches en Cancérologie de Toulouse, Universitré de Toulouse, PRESEmail verificata su inserm.fr
